BioVie Inc. Files 8-K with Corporate Updates

TL;DR

BioVie Inc. (BIVI) filed an 8-K on 3/6/24, updating corporate info and former name.

AI Summary

BioVie Inc. filed an 8-K on March 6, 2024, reporting on various events and financial statements. The filing indicates the company's principal executive offices are located at 680 W Nye Lane, Suite 201, Carson City, NV 89703, with a business phone number of (775) 888-3162. The company was formerly known as NanoAntibiotics, Inc. before a name change on June 25, 2013.

Why It Matters

This 8-K filing provides essential corporate information and updates for BioVie Inc., including its address, contact details, and former company name, which are crucial for investors and stakeholders to track the company's official status.

Risk Assessment

Risk Level: low — This filing is primarily administrative and informational, with no immediate financial or operational risks disclosed.

Key Players & Entities

• BIOVIE INC. (company) — Registrant
• March 6, 2024 (date) — Filing Date
• 680 W Nye Lane Suite 201 Carson City , NV 89703 (address) — Principal Executive Offices
• 775-888-3162 (phone_number) — Business Phone
• NANOANTIBIOTICS, INC. (company) — Former Company Name
• 20130625 (date) — Date of Name Change

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Marke
• $1.00 — at a combined public offering price of $1.00 per Share, or Pre-funded Warrant, and t
• $21 m — ny from the Offering were approximately $21 million, before deducting placement agent
• $2.2 million — and offering expenses of approximately $2.2 million. The Company intends to use the net pro
• $1.82 — he Exercise Price will be adjusted from $1.82 to $1.00, which was the price per share
• $1 — se Price will be adjusted from $1.82 to $1.00, which was the price per share of Co

Filing Documents

• bivi-20240306_8k.htm (8-K) — 32KB
• bivi-20240306_8kex99z1.htm (EX-99.1) — 10KB
• bivi-20240306_8kex99z2.htm (EX-99.2) — 15KB
• image_01.jpg (GRAPHIC) — 57KB
• image_02.jpg (GRAPHIC) — 116KB
• image_03.jpg (GRAPHIC) — 49KB
• image_04.jpg (GRAPHIC) — 51KB
• image_05.jpg (GRAPHIC) — 56KB
• image_06.jpg (GRAPHIC) — 46KB
• image_07.jpg (GRAPHIC) — 78KB
• image_08.jpg (GRAPHIC) — 96KB
• image_09.jpg (GRAPHIC) — 45KB
• image_10.jpg (GRAPHIC) — 83KB
• image_11.jpg (GRAPHIC) — 44KB
• image_12.jpg (GRAPHIC) — 54KB
• image_13.jpg (GRAPHIC) — 91KB
• image_14.jpg (GRAPHIC) — 44KB
• image_15.jpg (GRAPHIC) — 77KB
• image_16.jpg (GRAPHIC) — 63KB
• image_17.jpg (GRAPHIC) — 66KB
• image_18.jpg (GRAPHIC) — 63KB
• image_19.jpg (GRAPHIC) — 59KB
• image_20.jpg (GRAPHIC) — 46KB
• image_21.jpg (GRAPHIC) — 50KB
• image_22.jpg (GRAPHIC) — 49KB
• image_23.jpg (GRAPHIC) — 49KB
• image_24.jpg (GRAPHIC) — 47KB
• image_25.jpg (GRAPHIC) — 44KB
• image_26.jpg (GRAPHIC) — 76KB
• image_27.jpg (GRAPHIC) — 54KB
• image_28.jpg (GRAPHIC) — 45KB
• image_29.jpg (GRAPHIC) — 45KB
• image_30.jpg (GRAPHIC) — 90KB
• image_31.jpg (GRAPHIC) — 52KB
• image_32.jpg (GRAPHIC) — 74KB
• image_33.jpg (GRAPHIC) — 49KB
• image_34.jpg (GRAPHIC) — 44KB
• 0001520138-24-000098.txt ( ) — 3063KB
• bivi-20240306.xsd (EX-101.SCH) — 3KB
• bivi-20240306_lab.xml (EX-101.LAB) — 33KB
• bivi-20240306_pre.xml (EX-101.PRE) — 22KB
• bivi-20240306_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. Public Offering On March 6, 2024, the Company announced that it had closed the previously announced best efforts public offering (the " Offering ") of 15,000,000 shares (the " Shares ") of its class A common stock, par value $0.0001 per share (the " Common Stock "), pre-funded warrants (the " Pre-funded Warrants ") to purchase 6,000,000 shares of Common Stock, and warrants to purchase up to 10,500,000 shares of Common Stock (the " Common Warrants ") (CUSIP 09074F132) at a combined public offering price of $1.00 per Share, or Pre-funded Warrant, and the associated Common Warrant. The gross proceeds to the Company from the Offering were approximately $21 million, before deducting placement agent fees and offering expenses of approximately $2.2 million. The Company intends to use the net proceeds from the Offering primarily for working capital and general corporate purposes. Acuitas Warrant On March 6, 2024, the Company notified Acuitas Group Holdings, LLC ("Acuitas") of an adjustment to the exercise price (" Exercise Price ") of the warrant to purchase shares of Common Stock expiring July 15, 2028 (the " Acuitas Warrant ") that was issued by the Company to Acuitas pursuant to the Securities Purchase Agreement (the " SPA "), dated as of July 15, 2022, by and between the Company and Acuitas. Pursuant to Section 3(b) of the Acuitas Warrant, if the Company, at any time while the Acuitas Warrant is outstanding, issues shares of Common Stock at a price per share less than the Exercise Price, then the Exercise Price is reduced to such lower price per share. Accordingly, the Company gave notice to Acuitas that, effective at the close of business on March 6, 2024, the Exercise Price will be adjusted from $1.82 to $1.00, which was the price per share of Common Stock sold in the Offering. The foregoing descriptions of the SPA and Acuitas Warrant are not complete and are subject to and qualified in their entirety by reference to the full text of

Forward-Looking Statements

Forward-Looking Statements Certain of the statements made in this report are forward looking, such as those, among others, relating to the Company's expectations regarding the timing and completion of the Offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the Offering. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" in the Company's prospectus supplement on Form 424B5 filed with the SEC on March 4, 2024. The Company disclaims any intention or obligation to update or revise any

forward-looking statements, whether as a result of new information, future events or otherwise

forward-looking statements, whether as a result of new information, future events or otherwise.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 4.1 Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K/A filed with the SEC on July 18, 2022). 10.1 Securities Purchase Agreement, dated July 15, 2022, by and between the Company and Acuitas (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K/A filed with the SEC on July 18, 2022). 99.1 Press Release dated March 6, 2024. 99.2 Investor Presentation.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 6, 2024 BIOVIE INC. By: /s/ Joanne Wendy Kim Name: Joanne Wendy Kim Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR